Faron Pharmaceuticals Oy Stock Net Income
| FARN Stock | 165.00 10.00 5.71% |
Faron Pharmaceuticals Oy fundamentals help investors to digest information that contributes to Faron Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Faron Stock. The fundamental analysis module provides a way to measure Faron Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Faron Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -30.9 M | -29.4 M | |
| Net Loss | -30.9 M | -29.4 M | |
| Net Loss | -25.9 M | -24.6 M |
Faron | Net Income |
Faron Pharmaceuticals Oy Company Net Income Analysis
Faron Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Faron Pharmaceuticals Net Income | (30.94 M) |
Most of Faron Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Faron Pharmaceuticals Oy is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Faron Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Faron Pharmaceuticals Oy reported net income of (30.94 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United Kingdom stocks is notably higher than that of the company.
Faron Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Faron Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Faron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Faron Pharmaceuticals by comparing valuation metrics of similar companies.Faron Pharmaceuticals is currently under evaluation in net income category among its peers.
Faron Fundamentals
| Return On Equity | -39.61 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | 158.38 M | ||||
| Shares Outstanding | 104.62 M | ||||
| Shares Owned By Insiders | 31.81 % | ||||
| Shares Owned By Institutions | 10.35 % | ||||
| Price To Book | 151.61 X | ||||
| Price To Sales | 16.21 X | ||||
| Gross Profit | 803 K | ||||
| EBITDA | (28.37 M) | ||||
| Net Income | (30.94 M) | ||||
| Total Debt | 13.11 M | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (23.81 M) | ||||
| Earnings Per Share | (0.31) X | ||||
| Target Price | 1006.71 | ||||
| Number Of Employees | 34 | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 172.63 M | ||||
| Total Asset | 10.22 M | ||||
| Retained Earnings | (172.21 M) | ||||
| Working Capital | (6.14 M) | ||||
| Net Asset | 10.22 M |
About Faron Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Faron Pharmaceuticals Oy's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Faron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Faron Pharmaceuticals Oy based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Faron Stock Analysis
When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.